These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
197 related articles for article (PubMed ID: 11243687)
61. [Serological studies following immunization against horse influenza. 3. Reimmunization two years following first vaccination and antibody level during an interval of three years]. Pressler K Zentralbl Veterinarmed B; 1972 May; 19(5):426-33. PubMed ID: 5051224 [No Abstract] [Full Text] [Related]
62. Vaccination program in the response to the 2007 equine influenza outbreak in Australia. Perkins NR; Webster WR; Wright T; Denney I; Links I Aust Vet J; 2011 Jul; 89 Suppl 1():126-34. PubMed ID: 21711310 [TBL] [Abstract][Full Text] [Related]
63. Use of recombinant modified vaccinia Ankara viral vectors for equine influenza vaccination. Breathnach CC; Rudersdorf R; Lunn DP Vet Immunol Immunopathol; 2004 Apr; 98(3-4):127-36. PubMed ID: 15010222 [TBL] [Abstract][Full Text] [Related]
64. New assays to measure equine influenza virus-specific Type 1 immunity in horses. Paillot R; Kydd JH; MacRae S; Minke JM; Hannant D; Daly JM Vaccine; 2007 Oct; 25(42):7385-98. PubMed ID: 17881098 [TBL] [Abstract][Full Text] [Related]
65. Nationwide serological survey of equine influenza in Nigeria. Adeyefa CA; Hamblin C; Cullinane AA; McCauley JW Rev Elev Med Vet Pays Trop; 1996; 49(1):24-7. PubMed ID: 8881415 [TBL] [Abstract][Full Text] [Related]
67. [Efficiency of equine influenza vaccines including tetanus toxoid of combined vaccines]. Bommeli W; Kihm U; Löhrer J; Fey H Schweiz Arch Tierheilkd; 1980 Jan; 122(1):27-37. PubMed ID: 7384775 [No Abstract] [Full Text] [Related]
68. Duration of immunity induced by an adjuvanted and inactivated equine influenza, tetanus and equine herpesvirus 1 and 4 combination vaccine. Heldens JG; Kersten AJ; Weststrate MW; van den Hoven R Vet Q; 2001 Nov; 23(4):210-7. PubMed ID: 11765243 [TBL] [Abstract][Full Text] [Related]
69. Single radial immunodiffusion potency test for standardization of indigenous equine influenza vaccine. Gupta AK; Yadav MP; Uppal PK Indian J Exp Biol; 1993 Dec; 31(12):944-7. PubMed ID: 8112772 [TBL] [Abstract][Full Text] [Related]
70. Growth properties and immunogenicity of a virus generated by reverse genetics for an inactivated equine influenza vaccine. Ohta M; Bannai H; Kambayashi Y; Tamura N; Tsujimura K; Yamayoshi S; Kawaoka Y; Nemoto M Equine Vet J; 2022 Jan; 54(1):139-144. PubMed ID: 33527477 [TBL] [Abstract][Full Text] [Related]
71. Priming with AS03 A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: an open non-randomised extension of a double-blind randomised primary study. Leroux-Roels I; Roman F; Forgus S; Maes C; De Boever F; Dramé M; Gillard P; van der Most R; Van Mechelen M; Hanon E; Leroux-Roels G Vaccine; 2010 Jan; 28(3):849-57. PubMed ID: 19835828 [TBL] [Abstract][Full Text] [Related]
72. Overcoming maternal antibody interference by vaccination with human adenovirus 5 recombinant viruses expressing the hemagglutinin and the nucleoprotein of swine influenza virus. Wesley RD; Lager KM Vet Microbiol; 2006 Nov; 118(1-2):67-75. PubMed ID: 16939702 [TBL] [Abstract][Full Text] [Related]
73. Equine influenza vaccine efficacy: the significance of antigenic variation. Yates P; Mumford JA Vet Microbiol; 2000 May; 74(1-2):173-7. PubMed ID: 10799789 [TBL] [Abstract][Full Text] [Related]
74. Evaluating the effectiveness of the response to equine influenza in the Australian outbreak and the potential role of early vaccination. Garner MG; Cowled B; East IJ; Moloney BJ; Kung N Aust Vet J; 2011 Jul; 89 Suppl 1():143-5. PubMed ID: 21711314 [TBL] [Abstract][Full Text] [Related]
75. Equine influenza virus. Landolt GA Vet Clin North Am Equine Pract; 2014 Dec; 30(3):507-22. PubMed ID: 25282321 [TBL] [Abstract][Full Text] [Related]
76. Detection of antibodies to the nonstructural protein (NS1) of influenza A virus allows distinction between vaccinated and infected horses. Ozaki H; Sugiura T; Sugita S; Imagawa H; Kida H Vet Microbiol; 2001 Sep; 82(2):111-9. PubMed ID: 11423202 [TBL] [Abstract][Full Text] [Related]
77. A new modified live equine influenza virus vaccine: phenotypic stability, restricted spread and efficacy against heterologous virus challenge. Chambers TM; Holland RE; Tudor LR; Townsend HG; Cook A; Bogdan J; Lunn DP; Hussey S; Whitaker-Dowling P; Youngner JS; Sebring RW; Penner SJ; Stiegler GL Equine Vet J; 2001 Nov; 33(7):630-6. PubMed ID: 11770982 [TBL] [Abstract][Full Text] [Related]
78. Humoral and cell-mediated immune responses of old horses following recombinant canarypox virus vaccination and subsequent challenge infection. Adams AA; Sturgill TL; Breathnach CC; Chambers TM; Siger L; Minke JM; Horohov DW Vet Immunol Immunopathol; 2011 Feb; 139(2-4):128-40. PubMed ID: 21035197 [TBL] [Abstract][Full Text] [Related]
79. Biosecurity and vaccination strategies to minimise the effect of an equine influenza outbreak on racing and breeding. Arthur RJ; Suann CJ Aust Vet J; 2011 Jul; 89 Suppl 1():109-13. PubMed ID: 21711305 [TBL] [Abstract][Full Text] [Related]
80. Use of a blocking ELISA for antibodies to equine influenza virus as a test to distinguish between naturally infected and vaccinated horses: proof of concept studies. Kirkland PD; Delbridge G Aust Vet J; 2011 Jul; 89 Suppl 1():45-6. PubMed ID: 21711288 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]